The estimated Net Worth of Liisa I Nogelo is at least $218 Tisíc dollars as of 21 July 2021. Ms. Nogelo owns over 26,325 units of Surface Oncology Inc stock worth over $57,432 and over the last 6 years she sold SURF stock worth over $160,583. In addition, she makes $0 as Chief Legal Officer a Secretary at Surface Oncology Inc.
Liisa has made over 1 trades of the Surface Oncology Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 26,325 units of SURF stock worth $160,583 on 21 July 2021.
The largest trade she's ever made was selling 26,325 units of Surface Oncology Inc stock on 21 July 2021 worth over $160,583. On average, Liisa trades about 5,265 units every 0 days since 2018. As of 21 July 2021 she still owns at least 53,675 units of Surface Oncology Inc stock.
You can see the complete history of Ms. Nogelo stock trades at the bottom of the page.
Liisa I. Nogelo serves as Chief Legal Officer, Secretary of the Company. Prior to that she served as our General Counsel, Operations from July 2018 to January 2020. Prior to joining us, from August 2014 to July 2018, Ms. Nogelo led the legal team at the Broad Institute of MIT and Harvard, where she most recently served as the General Counsel, operations. Prior to the Broad Institute, from September 2007 to July 2014, Ms. Nogelo held senior positions on both the corporate and R&D legal teams at Biogen Idec Inc. (now Biogen Inc.), where she most recently served as Associate General Counsel and was the lead attorney for three late-stage drug development programs in amyotrophic lateral sclerosis (ALS) and hemophilia. Ms. Nogelo earned B.A. from Wellesley College and a J.D. from the UCLA School of Law.
Liisa Nogelo is 49, she's been the Chief Legal Officer a Secretary of Surface Oncology Inc since 2020. There are 6 older and 9 younger executives at Surface Oncology Inc. The oldest executive at Surface Oncology Inc is Elliott Sigal, 68, who is the Independent Director.
Liisa's mailing address filed with the SEC is C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE, MA, 02139.
Over the last 7 years, insiders at Surface Oncology Inc have traded over $69,198,912 worth of Surface Oncology Inc stock and bought 2,836,996 units worth $42,496,090 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, Surface Oncology Inc executives and independent directors trade stock every 37 days with the average trade being worth of $156,856. The most recent stock trade was executed by Alison Oneill on 1 August 2023, trading 7,042 units of SURF stock currently worth $6,619.
surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww
Surface Oncology Inc executives and other stock owners filed with the SEC include: